Movement Alert｜Royalty Pharma plc Falls 5.72% in Pre-Market Trading, S&P 500 Index Quarterly Rebalancing Inclusion Expectation Unmet

Market Focus

Sep 08

On September 8, Royalty Pharma plc fell 5.72% in pre-market trading, trading at $60.61/share, with Turnover of $83,100. The stock retreated sharply from its prior close of $63.96.

On the news front, the S&P 500 Index announced its latest quarterly rebalancing results after the close last Friday. Analyst Melissa Roberts had previously identified Royalty Pharma plc as a leading candidate for inclusion, given its total market capitalization of approximately $36.8 billion — well above the minimum threshold of $22.7 billion. However, the anticipated inclusion failed to materialize, prompting concentrated selling in after-hours and pre-market sessions.

Within the Pharmacy sector where Royalty Pharma plc belongs, the broader industry moved lower in tandem. Among individual stocks, Eli Lilly down 0.47%, Johnson & Johnson down 1.06%, Pfizer down 0.53%, Merck down 0.73%, AstraZeneca PLC down 0.88%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/1181700735"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181700735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181700735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181700735","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Royalty Pharma plc Falls 5.72% in Pre-Market Trading, S&P 500 Index Quarterly Rebalancing Inclusion Expectation Unmet","media":"Market Focus","content":"<p><p>On September 8, Royalty Pharma plc fell 5.72% in pre-market trading, trading at $60.61/share, with Turnover of $83,100. The stock retreated sharply from its prior close of $63.96.</p><p>On the news front, the S&P 500 Index announced its latest quarterly rebalancing results after the close last Friday. Analyst Melissa Roberts had previously identified Royalty Pharma plc as a leading candidate for inclusion, given its total market capitalization of approximately $36.8 billion — well above the minimum threshold of $22.7 billion. However, the anticipated inclusion failed to materialize, prompting concentrated selling in after-hours and pre-market sessions.</p><p>Within the Pharmacy sector where Royalty Pharma plc belongs, the broader industry moved lower in tandem. Among individual stocks, Eli Lilly down 0.47%, Johnson & Johnson down 1.06%, Pfizer down 0.53%, Merck down 0.73%, AstraZeneca PLC down 0.88%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Royalty Pharma plc Falls 5.72% in Pre-Market Trading, S&P 500 Index Quarterly Rebalancing Inclusion Expectation Unmet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Royalty Pharma plc Falls 5.72% in Pre-Market Trading, S&P 500 Index Quarterly Rebalancing Inclusion Expectation Unmet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-08 18:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 8, Royalty Pharma plc fell 5.72% in pre-market trading, trading at $60.61/share, with Turnover of $83,100. The stock retreated sharply from its prior close of $63.96.</p><p>On the news front, the S&P 500 Index announced its latest quarterly rebalancing results after the close last Friday. Analyst Melissa Roberts had previously identified Royalty Pharma plc as a leading candidate for inclusion, given its total market capitalization of approximately $36.8 billion — well above the minimum threshold of $22.7 billion. However, the anticipated inclusion failed to materialize, prompting concentrated selling in after-hours and pre-market sessions.</p><p>Within the Pharmacy sector where Royalty Pharma plc belongs, the broader industry moved lower in tandem. Among individual stocks, Eli Lilly down 0.47%, Johnson & Johnson down 1.06%, Pfizer down 0.53%, Merck down 0.73%, AstraZeneca PLC down 0.88%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RPRX","symbol_name":"Royalty Pharma plc","start_time":0,"source_url":"","article_id":"1181700735","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181700735","pubTimestamp":1788863532,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 8, Royalty Pharma plc fell 5.72% in pre-market trading, trading at $60.61/share, with Turnover of $83,100. The stock retreated sharply from its prior close of $63.96.On the news front,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RPRX":"Royalty Pharma plc"},"translate_title":"走势警报|Royalty Pharma plc 盘前交易下跌 5.72%，标普500指数季度再平衡纳入预期未达到","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":1},"content_text":"On September 8, Royalty Pharma plc fell 5.72% in pre-market trading, trading at $60.61/share, with Turnover of $83,100. The stock retreated sharply from its prior close of $63.96.On the news front, the S&P 500 Index announced its latest quarterly rebalancing results after the close last Friday. Analyst Melissa Roberts had previously identified Royalty Pharma plc as a leading candidate for inclusion, given its total market capitalization of approximately $36.8 billion — well above the minimum threshold of $22.7 billion. However, the anticipated inclusion failed to materialize, prompting concentrated selling in after-hours and pre-market sessions.Within the Pharmacy sector where Royalty Pharma plc belongs, the broader industry moved lower in tandem. Among individual stocks, Eli Lilly down 0.47%, Johnson & Johnson down 1.06%, Pfizer down 0.53%, Merck down 0.73%, AstraZeneca PLC down 0.88%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}